Chibaudel et al.,(1313. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, et al. Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study. Cancer Med. 2015;4(5):721-31.) |
42 pacientes Média de idade: 56 anos Carcinoma de orofaringe |
Cetuximab (IV) D1, 8 e 15 Docetaxel Cisplatina D1, 8 e15 5-FU 750mg/m2 D1-5 |
G0 = 27 (65,8%) G1 = 5 (12,2%) G2 = 4 (9,8%) G3 = 5 (12,2%) G4 = 0 |
Bano et al.,(1414. Bano N, Najam R, Qazi F, Mateen A. Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. Asian Pac J Cancer Prev. 2014;15(19):8089-93.) |
38 pacientes Média de idade: 61 anos Carcinoma coloretal Protocolo 1 = 13 pacientes Protocolo 2 = 12 pacientes Protocolo 3 = 5 pacientes Protocolo 4 = 8 pacientes |
Protocolo 1 - FOLFOX 4 - Oxiplatina 85mg/m2 (IV) D1 - 5-FU 400mg/m2 IV bólus + 600mg/m2 contínuo D1 e 2 - Leucovorin 200mg/m2 D1 e 2 Protocolo 2 - FOLFOX 6 - Oxiplatina 100mg/m2 (IV) D1 - 5-FU 400mg/m2 IV bólus + 2.400mg/m2 contínuo D1 e 2 - Leucovorin 400mg/m2 D1 e 2 Protocolo 3 - mFOLFOX 6 - Oxiplatina 100mg/m2 (IV) D1 - 5-FU 2.000mg/m2 contínuo D1 e 2 - Leucovorin 100mg/m2 D1 e 2 Protocolo 4 - FOLFOX 7 - Oxiplatina 130mg/m2 (IV) D1 - 5-FU 2.400mg/m2 contínuo D1 e 2 - Leucovorin 400mg/m2 D1 e 2 |
Protocolo 1 - G0 = 24% G1 e 2 = 65% G3 e 4 = 11%
Protocolo 2 - G0 = 38% G1 e 2 = 56% G3 e 4 = 6%
Protocolo 3 - G0 = 21% G1 e 2 = 79% G3 e 4 = 0
Protocolo 4 - G0 = 7% G1 e 2 = 90% G3 e 4 = 3% |
Wang et al.,(1515. Wang HM, Hsu CL, Hsieh CH, Fan KH, Lin CY, Chang JT. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. Biomed J. 2014;37(3):133-40.) |
65 pacientes Média de idade: não informada Carcinoma oro e hipofaringe |
Cisplatina 50mg/m2 (IV) D1 Tegafur 800mg (VO) D1-14 Leucovorin 60mg (VO) D1-14 |
G0 = 3,1% G1 = 1,5% G2 = 15,4% G3 = 73,8% G4 = 6,2% |
Aapro et al.,(1616. Aapro M, Andre F, Blackwell K, Clavo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25(4):763-73. Review.) |
1. Carcinoma renal = 274 pacientes 2. Tumores neuroendócrinos = 204 pacientes 3. Câncer de mama = 482 pacientes Média de idade: não informada |
Everolimus |
1. G1-G4 = 44% 2. G1-G4 = 64% 3. G1-G4 = 59% |
Tao et al.,(1717. Tao CJ, Liu X, Tang LL, Mao YP, Chen L, Li WF, et al. Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chin J Cancer. 2013;32(10):525-32.) |
34 pacientes Média de idade: 16 anos Carcinoma nasofaríngeo |
Cisplatina 5-FU Radioterapia |
G0 = 0 G1 = 10 (29,4%) G2 = 14 (41,2%) G3 = 9 (26,5%) G4 = 1 (2,9%) |
Lin et al.,(1818. Lin HX, Hua YJ, Chen QY, Luo DH, Sun R, Qiu F, et al. Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013;32(9):502-11.) |
124 pacientes Média de idade: 42 anos Carcinoma nasofaríngeo |
3 ciclos 5-FU 750mg/m2 D1-5 Radioterapia |
1. G0 = 82 G1 e 2 = 42 G3 e 4 = 0 2. G0 = 58 G1 e 2 = 43 G3 e 4 = 14 3. G0 = 0 G1 e 2 = 64 G3 e 4 = 60 |
Iwata et al.,(1919. Iwata H, Fujii H, Masuda N, Mukai H, Nishimura Y, Katsura K, et al. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. Breast Cancer. 2015;22(2):192-200.) |
51 pacientes Média de idade: 55 anos Carcinoma de mama |
Lapatinib 1.250mg 1 vez/dia Capecitabine 1.000mg/m2 2 vezes/dia |
G0 = 30 (59%) G1 = 21 (41%) G2 = 0 G3 = 0 G4 = 0 |
Palappallil et al.,(2020. Palappallil DS, Nair BL, Jayakumar KL, Puvathalil RT. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycincyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer. 2011;48(1):68-73.) |
1. 50 pacientes 2. 50 pacientes Média de idade: 45 (20-70) anos Carcinoma de mama |
1. FAC 5-FU 500mg/m2 Doxorrubicina 50mg/m2 Ciclofosfamida 500mg/m2 2. AC-P Doxorrubicina 60mg/m2 Ciclofosfamida 600mg/m2 Paclitaxel 175mg/m2
|
1. G1-G4 = 45 (90%) 2. G1-G4 = 2 (4%) |
Baird et al.,(2121. Baird R, Biondo A, Chhaya V, McLachlan J, Karpathakis A, Rahman S, et al. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. Br J Cancer. 2011;104(1):43-50.) |
1. 200 pacientes 2. 200 pacientes Média de idade: 65 anos Carcinoma coloretal |
1. CAPOX 2000 Capecitabine 2.000mg/m2 D1-14 Oxiplatina 130mg/m2 D1 2. CAPOX 1.700 Capecitabine 1.700mg/m2 D1-14 Oxiplatina 130mg/m2 D1 Cetuximabe |
1. G1 = 22 (11%) G2 = 5 (2,5%) G3 = 0 (0%) G4 = 0 (0%) 2. G1 = 22 (11%) G2 = 5 (2,5%) G3 = 2 (1%) G4 = 0 (0%) |
Lee et al.,(2222. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20(8):1402-7.) |
32 pacientes Média de idade: 53 anos Carcinoma coloretal |
Capecitabine 2.000mg/m2 D1-14 Cisplatina 60mg/m2 D1 |
G1-G2 = 4 (12,9%) G3-G4 = 1(3,2%) |
Abromowitch et al.,(2323. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS; Children's Oncology Group. Shortened intensified multiagent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol. 2008;143(2):261-7.) |
1. 85 pacientes 2. 82 pacientes 3.1. 76 pacientes 3.2. 73 pacientes 3.3. 70 pacientes 3.4. 68 pacientes 3.5. 65 pacientes 3.6. 65 pacientes Média de idade: 5,1 anos Leucemia linfoblástica |
1. Indução Vincristina 1,5mg/m2 D0, 7 e 14 Daunomicina 60mg/m2 D1 e 2 Ciclofosfamida 1.200mg/m2 D0 L-Asparaginase 2. Consolidação Vincristina 1,5mg/m2 D0 e 7 Citarabina 2.000mg/m2 D0 e 1 Etoposide 200mg/m2 D0 e 1 Tioguanina 300mg/m2 D0-3 Metotrexato 1.000mg/m2 (IV) 3. Manutenção Ciclofosfamida 1.200mg/m2 D0 Tioguanina 300mg/m2 D0-3 Vincristina 15mg/m2 D14 e 21 Doxorrubicina 30mg/m2 D14 Ciclofosfamida 1.200mg/m2 D0 Vincristina 15mg/m2 D28 Metotrexato 1.000mg/m2 (IV) |
1. Indução G1-G4 = 0 (0%) 2. Consolidação G1-G4 = 5 (6,1%) 3. Manutenção 3.1 G1-G4 = 3 (3,9%) 3.2 G1-G4 = 6 (8,2%) 3.3 G1-G4 = 2 (2,9%) 3.4 G1-G4 = 3 (4,4%) 3.5 G1-G4 = 1 (1,5%) 3.6 G1-G4 = 4 (6,2%) |
Shin et al.,(2424. Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, et al. Treatment Outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008;23(3):439-44.) |
17 pacientes Média de idade: 38 anos Linfo-histiocitose hemofagocítica |
CHOP Ciclofosfamida 750mg/m2 D1 Doxorrubicina 50mg/m2 D1 Vincristina 1,4mg/m2 D1 Predinisona 40mg/m2 D1-5 |
G0 = 10 (58,84%) G1 = 2 (11,76%) G2 = 2 (11,76%) G3 = 3 (17,64%) G4 = 0 |
Blijlevens et al.,(2525. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S; European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26(9):1519-25.) |
1. 109 pacientes com mieloma múltiplo Média de idade: 56,8 anos 2. 88 pacientes com linfoma não Hodgkin Média de idade: 50 anos |
1. Melfalan 200mg/m2 2. BEAM Carmustina 300mg/m2 Etoposide 800mg/m2 Citarabina 800-1.600mg/m2 Melfalan 140mg/m2
|
1. G0 = 10% G1-G2 = 44 % G3-G4 = 46% 2. G0 = 17% G1-G2 = 41% G3-G4 = 42% |
Fadda et al.,(2626. Fadda G, Campus G, Lugliè P. Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy. BMC Oral Health. 2006;6:13.) |
231 pacientes pré-TCTH Média de idade: 7,6 anos |
Agentes alquilantes 1. Melfalan 2. Bussulfano 3. Outros |
1. Melfalan G0 = 20 G1-G4 = 24 2. Bussulfano G0 = 34 G1-G4 = 153 3. Outros G0 = 42 G1-G4 = 64 |
Castagna et al.,(2727. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol. 2007;82(2):122-7.) |
1. 29 pacientes 2. 24 pacientes Média de idade: 31 anos TCTH Linfoma Hodgkin |
1. Melfalan 200mg/m2 D1 2. BEAM Carmustina 300mg/m2 D1 Etoposide 800mg/m2 D1-4 Citarabina 1.600mg/m2 D1-4 Melfalan 140mg/m2 D1 |
1. Melfalan - G3-G4 = 17 (60%) 2. BEAM - G3-G4 = 12 (50%) |
Oh et al.,(2828. Oh DY, Kim TY, Kwon JH, Lee JJ, Joh Y, Kim DW, et al. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol. 2005;35(7):380-5.) |
43 pacientes Média de idade: 55 anos Carcinoma gástrico |
Docetaxel 70mg/m2 5-FU 1200mg/m2 Cisplatina 40mg/m2
|
G1 = 1 (2,3%) G2 = 1 (2,3%) G3-G4 = 0 (0) |
Schmid et al.,(2929. Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432-40.) |
93 pacientes 1. 48 2. 45 Média de idade: 1. 29 anos 2. 25 anos Carcinoma de mama |
1. AT Doxorrubicina 60mg/m2 Paclitaxel 200mg/m2 2. HDCT Mitoxantrona 45mg/m2 Ciclofosfamida 2400mg/m2 Etoposide 2500mg/m2
|
1. AT - G3-G4 = 4,6% 2. HDCT - G3-G4 = 26,3% |
Saini et al.,(3030. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer. 2003;88(12):1859-65.) |
716 pacientes Média de idade: 63 anos Carcinoma coloretal |
1. 5-FU 300mg/m2 IV contínuo 2. 5-FU 425mg/m2 bólus D1-5 |
1. G3-G4 = 3,6% 2. G3-G4 = 19,6% |
Kremens et al.,(3131. Kremens B, Gruhn B, Klingebiel T, Hasan C, Laws HJ, Koscielniak E, et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002;30(12):893-8.) |
20 pacientes Média de idade: 5,67 anos Tumor de Wilms |
Melfalan 200mg/m2 D1-5 Etoposide Carboplatina |
G3-G4 = 10 (50%) |
Lacayo et al.,(3232. Lacayo NJ, Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, et al. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia. 2002; 16(5):920-7.) |
38 pacientes 1. 15 2. 23 Média de idade: não informado Leucemia mieloide aguda |
1. DAT Daunomicina 45mg/m2 D1-3 Citarabina 100mg/m2 D1-7 Tioguanina 100mg/m2 D1-7 2. DAT + citarabina altas doses DAT Citarabina 1.000mg/m2 2 vezes/dia D1-7 |
1. DAT - G3-G4 = 2 (13%) 2. DAT + Citarabi-na altas doses - G3-G4 = 8 (35%) |
Leblond et al.,(3333. Leblond V, Lévy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, Remenieras L, Porcher R, Gardembas M, Marit G, Deconinck E, Desablens B, Guilhot F, Philippe G, Stamatoullas A, Guibon O; French Cooperative Group on Chronic Lymphocytic Leukemia and Macroglobulinemia. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98(9):2640-4.) |
1. 46 pacientes 2. 46 pacientes Média de idade: 64 anos Macroglobulinemia de Waldenström |
1. FAMP Fludarabina 25mg/m2 D1-5 2. CAP Ciclofosfamida 750mg/m2 D1 Doxorrubicina 25mg/m2 D1 Prednisona 40mg/m2 D1-5 |
1. FAMP - G1-G4 = 0 2. CAP - G1-G4 = 10 |
Lissoni et al.,(3434. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, et al. Cisplatin, epirubicin and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol. 1997;8(10):969-72.) |
49 pacientes Média de idade: 53,7 anos Adenocarcinoma endometrial |
Epirubicina 70mg/m2 Paclitaxel 175mg/m2 Cisplatina 70mg/m2
|
G1 = 12 G2 = 0 G3 = 0 G4 = 0 |
Wang et al.,(3535. Wang WS, Tzeng CH, Chiou TJ, Liu JH, Hsieh RK, Yen CC, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-hodgkin's lymphoma. Jpn J Clin Oncol. 1997;27(3):154-7. Review.) |
16 pacientes Média de idade: 42,7 anos Linfoma não Hodgkin refratário |
Citarabina 3.000mg/m2 2 vezes/dia D1-4 Mitoxantrona 6mg/m2 D1-5 |
G1 = 6 G2 = 2 G3 = 5 G4 = 1 |
Anderson et al.,(3636. Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomized study of bolous vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer. 1993;67(6):1385-90.) |
148 pacientes 1. Bólus =78 2. Infusão= 70 Média de idade: 61 anos Carcinoma de pequenas células pulmão |
Doxorrubicina 35mg/m2 D1 Etoposide 100mg/m2 D1-5 Ifosfamida 5.000mg/m2 D1 |
1. Bólus - G1-G4 = 24 (31%) 2. Infusão - G1-G4 = 37 (53%) |
Bishop et al.,(3737. Bishop JF, Lowenthal RM, Joshua D, Mattews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75(1):27-32.) |
274 pacientes Média de idade: não informado Leucemia não linfocítica aguda |
Daunorrubicina 50mg/m2 D1-3 Etoposide 75mg/m2 D1-7 |
G3-G4 = 26% |
Clavel et al.,(3838. Clavel M, Cognetti F, Dodion P, Wildiers J, Rosso R, Rossi A, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer. 1987;60(6):1173-7.) |
1. 93 pacientes 2. 92 pacientes Média de idade: 57,5 anos Carcinoma de cabeça e pescoço |
1. CABO Cisplatina 50mg/m2 D4 Metotrexato 40mg/m2 D1 e 15 Vincristina 2mg/m2 D1, 8 e15 Bleomicina 10mg/m2 D1, 8 e15 2. ABO Metotrexato 40mg/m2 D1, 8 e 15 Vincristina 2mg/m2 D1, 8 e 15 Bleomicina 10mg/m2 D1, 8 e 15 |
1. G3-G4 = 24% 2. G3-G4 = 31 |